NeuroOne Medical Technologies (NMTC) AI Stock Analysis

• Market Cap: $39.60M
• Dividend Yield: N/A
• Average Volume (3M): 532.45K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: 145.48%
• EPS Growth: 67.36%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 49,999,520
• 10 Day Avg. Volume: 702,340
• 30 Day Avg. Volume: 532,447
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 3.81
• Enterprise Value/Gross Profit: 6.72
• Enterprise Value/Ebitda: -5.59
• 1Y Price Target: $3.00
• Price Target Upside: 279.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: $1.00 ▲(26.58% Upside)

NeuroOne Medical Technologies' overall stock score is driven by strong revenue growth and positive earnings call sentiment. However, the company's ongoing profitability challenges and negative valuation metrics weigh heavily on the score. Technical indicators suggest a bearish trend, but potential for a rebound exists as the stock approaches oversold levels.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, which are crucial for long-term business sustainability.

Debt-Free Status

Being debt-free enhances financial stability and flexibility, allowing the company to invest in growth opportunities without the burden of interest payments.

FDA Clearance

FDA clearance for new products strengthens market position and opens new revenue streams, supporting long-term growth and innovation.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder reinvestment in R&D and limit competitive positioning, impacting long-term viability.

Cash Flow Management

Declining cash flow growth indicates potential liquidity issues, which could restrict operational flexibility and investment capacity.

Lack of International Sales

Limited international presence restricts market expansion and revenue diversification, potentially impacting long-term growth prospects.

NeuroOne Medical Technologies Business Overview & Revenue Model

Company Description

NeuroOne Medical Technologies, Inc. is a medical technology company focused on developing innovative solutions for neurological disorders. The company operates primarily in the neuromodulation and neurodiagnostics sectors, offering advanced medical devices designed to improve the treatment of conditions such as epilepsy and chronic pain. Core products include thin-film electrodes for brain monitoring and neurostimulation, which are used in a variety of clinical applications to enhance patient care and surgical outcomes.

How the Company Makes Money

NeuroOne generates revenue through the sale of its medical devices and technology solutions to hospitals, clinics, and medical professionals. The company leverages a direct sales model, often partnering with distributors to reach a broader market. Key revenue streams include product sales of their thin-film electrode systems and neurostimulation devices, as well as potential licensing agreements for their proprietary technology. Additionally, strategic partnerships with healthcare providers and research institutions facilitate clinical trials and product validation, ultimately contributing to revenue growth as their products gain acceptance in the medical community.

NeuroOne Medical Technologies Financial Statement Overview

Summary

NeuroOne Medical Technologies shows strong revenue growth but struggles with profitability, as indicated by negative net profit margins and EBIT margins. The balance sheet is stable with low leverage, but the company has negative returns on equity. Cash flow management is concerning with declining free cash flow growth and negative operating cash flow ratios.

Income Statement

NeuroOne Medical Technologies shows a positive revenue growth rate of 15.11% TTM, indicating a strong upward trajectory in sales. However, the company struggles with profitability, as evidenced by negative net profit margins and EBIT margins, which reflect ongoing operational challenges. The gross profit margin has improved to 54.19% TTM, suggesting better cost management, but the overall profitability remains a concern.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 0.28 TTM, indicating a relatively low level of leverage, which is a positive sign of financial stability. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio stands at 75.58%, suggesting a strong equity base relative to total assets.

Cash Flow

The cash flow statement highlights a decline in free cash flow growth by -17.52% TTM, pointing to potential cash management issues. The operating cash flow to net income ratio is negative, indicating that the company is not generating sufficient cash from operations to cover its net losses. However, the free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is somewhat aligned with net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.63M	3.45M	1.95M	171.17K	178.15K	1.93M
Gross Profit	3.75M	1.08M	456.52K	-70.79K	-97.75K	63.12K
EBITDA	-4.51M	-11.84M	-11.76M	-9.91M	-9.80M	-4.85M
Net Income	-5.34M	-12.32M	-11.86M	-10.00M	-9.95M	-13.64M
Balance Sheet
Total Assets	10.82M	5.37M	8.10M	12.82M	7.94M	4.76M
Cash, Cash Equivalents and Short-Term Investments	8.04M	1.46M	5.32M	11.14M	6.90M	4.04M
Total Debt	295.72K	260.16K	184.40K	202.90K	315.67K	1.32M
Total Liabilities	2.64M	4.55M	1.85M	3.22M	1.38M	2.69M
Stockholders Equity	8.18M	822.01K	6.25M	9.60M	6.55M	2.07M
Cash Flow
Free Cash Flow	-4.09M	-11.13M	-13.27M	-7.79M	-8.67M	-3.55M
Operating Cash Flow	-3.98M	-11.01M	-12.89M	-7.52M	-8.60M	-3.43M
Investing Cash Flow	-108.04K	-120.20K	2.65M	-3.24M	-67.08K	-122.43K
Financing Cash Flow	10.51M	7.27M	7.40M	12.02M	11.53M	7.32M

NeuroOne Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.79
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.79 is below the 20-day moving average (MA) of 0.88, below the 50-day MA of 0.86, and below the 200-day MA of 0.82, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.16 is Neutral, neither overbought nor oversold. The STOCH value of 20.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.

NeuroOne Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	―	$52.44M	―	-1.62%	―	3.30%	-112.70%
ECOR	―	$39.02M	―	-210.58%	―	30.16%	22.51%
NMTC	―	$39.60M	-5.01	-95.39%	―	145.48%	67.36%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
RBOT	―	$38.31M	-0.58	-125.63%	―	―	6.48%
IINN	―	$28.18M	―	―	―	―	―

NeuroOne Medical Technologies Corporate Events

NeuroOne Reports Record Revenue Growth for 2025

On October 6, 2025, NeuroOne Medical Technologies announced a significant increase in their preliminary unaudited product revenue for the fiscal year 2025, reaching a record $9.1 million, a 163% growth from the previous year. This growth is attributed to the expanded use and positive outcomes of their OneRF® Ablation system for epilepsy patients. The company also reported cash and cash equivalents of $6.6 million as of September 30, 2025. The complete financial results are expected in December 2025, and stakeholders are advised to exercise caution as these results are preliminary and subject to adjustments.

The most recent analyst rating on (NMTC) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.

NeuroOne’s Earnings Call Highlights Growth and Stability

The recent earnings call for NeuroOne Medical Technologies Corporation was marked by a notably positive sentiment. The company showcased significant revenue growth, successful patient outcomes, and new market expansions, all contributing to a sense of financial stability. Although there were concerns about the lack of international sales, the overall achievements and progress made by the company overshadowed these challenges.

NeuroOne Gains FDA Clearance for Nerve Ablation System

On August 18, 2025, NeuroOne Medical Technologies Corporation announced it received FDA 510(k) clearance for its OneRF® Trigeminal Nerve Ablation System. This clearance allows the company to market the system for creating radiofrequency lesions to treat pain or for functional neurosurgical procedures, potentially enhancing its market position and offering new solutions for stakeholders.

The most recent analyst rating on (NMTC) stock is a Buy with a $1.45 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.

NeuroOne Updates Prospectus for $6.75 Million Offering

On December 21, 2022, NeuroOne Medical Technologies Corporation entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, allowing the company to sell shares of its common stock through an ‘at the market offering.’ On August 15, 2025, the company filed an updated Prospectus Supplement for the sale of up to $6.75 million of shares, potentially impacting its financial strategy and market presence.

The most recent analyst rating on (NMTC) stock is a Buy with a $1.45 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.

NeuroOne Reports Strong Q3 2025 Financial Growth

NeuroOne Medical Technologies Corporation, a medical technology firm focused on innovative solutions for neurological disorders, has reported impressive financial results for the third quarter of fiscal year 2025. The company, which specializes in minimally invasive and high-definition solutions for EEG recording, monitoring, ablation, drug delivery, and stimulation, has seen significant growth in its financial performance.